Health Catalyst Inc
Health Catalyst Inc provides data and analytics solutions to healthcare organizations to improve clinical, financial, and operational outcomes.
Business. Health Catalyst Inc (HCAT.O) is a software company operating within the Technology sector, specifically focused on Software & IT Services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Health Catalyst is listed under the ticker HCAT.O.
Analyst recommendations
9 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
- Peers
- EarningsQ2 2026 earnings (expected)2026-07-28 · estimated · ServiceNow (NOW)
- EarningsQ2 2026 earnings (expected)2026-08-28 · estimated · Salesforce (CRM)
- Macro
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
- Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
- Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
- Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Health Catalyst Inc (HCAT.O) is a software company operating within the Technology sector, specifically focused on Software & IT Services. The firm generates revenue through a subscription model, with key performance indicators including annual recurring revenue and net revenue retention. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Health Catalyst is listed under the ticker HCAT.O.
Health Catalyst operates with a market capitalization of $86.1 million and a price-to-book ratio of 0.24, indicating a significant discount to its book value. The company holds $201.4 million in cash and equivalents but carries $228.4 million in long-term debt, resulting in a net cash position of -$27.0 million. This negative net cash position raises liquidity concerns despite a current ratio of 4.31, which suggests the company can cover its short-term liabilities multiple times over.
Profitability metrics show Health Catalyst is currently unprofitable, with a net loss of $20.6 million and an operating loss of $22.8 million. The company's return on equity is -5.76%, and its return on assets is -2.96%, both significantly below the industry median for software firms. Gross profit of $36.6 million represents 49.0% of revenue, which is in line with the industry average for health care technology firms.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks, particularly in the healthcare technology space. The company's operating cash flow of $10.3 million is positive, but its free cash flow is negative at -$12.8 million, indicating that capital expenditures are outpacing operating cash flow.
Looking ahead, Health Catalyst is expected to see a modest improvement in revenue, with a projected growth rate of 2.5% for the current fiscal year and 3.0% for the next fiscal year. However, the company's operating losses are expected to persist, with a narrowing of the operating loss margin from -30.5% to -28.0% over the next 12 months. The risk assessment indicates a medium liquidity risk due to the negative net cash position and a low dilution risk, with no near-term pressure from share issuance.
Recent filings and transcripts highlight ongoing challenges in scaling the business while maintaining profitability. The company has not issued any new shares in the past 12 months, and there are no indications of a near-term capital raise. Analysts have a mixed outlook, with a mean price target of $1.96 and a median of $2.00, suggesting a potential upside of 67.5% from the current market price of $1.17.
- Health Catalyst is trading at a significant discount to book value, with a price-to-book ratio of 0.24.
- The company is unprofitable, with a net loss of $20.6 million and a return on equity of -5.76%.
- Despite a strong current ratio of 4.31, the company has a negative net cash position of -$27.0 million.
- Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
- Analysts project a potential upside of 67.5% from the current market price, with a mean price target of $1.96.
- The company is expected to narrow its operating loss margin from -30.5% to -28.0% over the next 12 months.
Bull / Bear case
Generated · model-assistedAnalysts project 18.7% upside to a mean price target of $1.96 from the current $1.65.
The company maintains a medium leverage band with a debt-to-equity ratio of 0.62.
The company faces high credit risk according to internal risk flag assessments.
Return on equity of -5.76% significantly underperforms the software cohort median of 2.8%.
In focus — financials by report
Revenue $74.7M, −6,2% YoY; Operating income −391,9% YoY.
- ▍Revenue $74.7M, −6,2% YoY
- ▍Operating income −391,9% YoY
- ▍Net income −340,3% YoY
- ▍Free cash flow −454,2% YoY
- ▍Net margin -121.9%
Revenue $76.3M, −0,0% YoY; Operating income −27,9% YoY.
- ▍Revenue $76.3M, −0,0% YoY
- ▍Operating income −27,9% YoY
- ▍Net income −51,0% YoY
- ▍Free cash flow −59,8% YoY
- ▍Net margin -29.1%
Revenue $80.7M, +6,3% YoY; Operating income −134,7% YoY.
- ▍Revenue $80.7M, +6,3% YoY
- ▍Operating income −134,7% YoY
- ▍Net income −203,2% YoY
- ▍Free cash flow −367,6% YoY
- ▍Net margin -50.8%
Revenue $79.4M, +6,3% YoY; Operating income +11,6% YoY.
- ▍Revenue $79.4M, +6,3% YoY
- ▍Operating income +11,6% YoY
- ▍Net income −15,3% YoY
- ▍Free cash flow −30,9% YoY
- ▍Net margin -29.9%
Revenue $79.6M; Operating income -$17.5M.
- ▍Revenue $79.6M
- ▍Operating income -$17.5M
- ▍Net margin -26.0%
Revenue $76.4M; Operating income -$13.7M.
- ▍Revenue $76.4M
- ▍Operating income -$13.7M
- ▍Net margin -19.3%
Revenue $75.9M; Operating income -$15.8M.
- ▍Revenue $75.9M
- ▍Operating income -$15.8M
- ▍Net margin -17.8%
Revenue $74.7M; Operating income -$22.8M.
- ▍Revenue $74.7M
- ▍Operating income -$22.8M
- ▍Net margin -27.6%
Revenue $311.1M, +1,5% YoY; Operating income −130,4% YoY.
- ▍Revenue $311.1M, +1,5% YoY
- ▍Operating income −130,4% YoY
- ▍Net income −156,1% YoY
- ▍Free cash flow −235,7% YoY
- ▍Net margin -57.2%
Revenue $306.6M, +3,6% YoY; Operating income +45,0% YoY.
- ▍Revenue $306.6M, +3,6% YoY
- ▍Operating income +45,0% YoY
- ▍Net income +41,2% YoY
- ▍Free cash flow +50,8% YoY
- ▍Net margin -22.7%
Revenue $295.9M, +7,1% YoY; Operating income +9,4% YoY.
- ▍Revenue $295.9M, +7,1% YoY
- ▍Operating income +9,4% YoY
- ▍Net income +14,0% YoY
- ▍Free cash flow +15,3% YoY
- ▍Net margin -39.9%
Revenue $276.2M, +14,2% YoY; Operating income +2,5% YoY.
- ▍Revenue $276.2M, +14,2% YoY
- ▍Operating income +2,5% YoY
- ▍Net income +10,3% YoY
- ▍Free cash flow +20,6% YoY
- ▍Net margin -49.7%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,14 |
| Revenue | —no estimate | —no estimate | 280,2M USD |
| Operating income | —no estimate | —no estimate | -24,4M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Health Catalyst Inc Market data — financials · 2026-05-28
- Health Catalyst Inc Market data — analyst estimates · 2026-05-28
- Health Catalyst Inc Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2024-12-310,00 %$4M
- Investment Managers · as of 2024-06-300,00 %$35M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Ben AlbertPresident, Chief Executive Officer, Director
Insider activity
- Director, CEO · Common StockOther 34 485 @ $1,69$58K · 2026-06-10
- General Counsel · Common StockOther 13 779 @ $1,37$19K · 2026-06-01
- Director · Common StockOther 12 710 · 2026-06-01
- Chief Financial Officer · Common StockOther 18 804 @ $1,37$26K · 2026-06-01
- Director, CEO · Common StockOther 336 @ $1,37$460 · 2026-06-01
- Chief People Officer · Common StockOther 8 519 @ $1,37$12K · 2026-06-01
- Director, CEO · Common StockOther 310 @ $1,34$417 · 2026-05-01
- Director · Common StockOther 154 808 · 2026-05-01
- Director, CEO · Common StockOther 1 124 · 2026-04-29
- Director, CEO · Common StockOther 70 455 @ $1,85$130K · 2026-03-10
- General Counsel · Common StockOther 20 838 @ $1,66$35K · 2026-03-02
- Chief Financial Officer · Common StockOther 26 970 @ $1,66$45K · 2026-03-02
- Director, CEO · Common StockOther 4 966 @ $1,66$8K · 2026-03-02
- Chief People Officer · Common StockOther 13 836 @ $1,66$23K · 2026-03-02
- Director · Common StockOther 8 361 · 2026-03-01
- Director, CEO · Common StockOther 13 304 @ $1,75$23K · 2026-02-26
- Chief People Officer · Common StockOther 4 471 @ $1,75$8K · 2026-02-26
- General Counsel · Common StockOther 6 317 @ $1,75$11K · 2026-02-26
- Chief Financial Officer · Common StockOther 7 522 @ $1,75$13K · 2026-02-26
- Director, CEO · Common StockOther 38 833 · 2026-02-25
- Director, CEO · Common StockOther 930 000 · 2026-02-25
- Chief People Officer · Common StockOther 191 500 · 2026-02-25
- Chief People Officer · Common StockOther 13 195 · 2026-02-25
- General Counsel · Common StockOther 289 000 · 2026-02-25
- General Counsel · Common StockOther 16 473 · 2026-02-25
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -14.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -130.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -95.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -156.1%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -59.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -121.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -121.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -79.6%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -40.1%Derived (calculated)
- Net margin (FY 2025-12-31): -57.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.05xDerived (calculated)
- Current ratio (FY 2025-12-31): 1.89xDerived (calculated)
- Return on assets (FY 2025-12-31): -35.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -48.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -41.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -72.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -32.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.5%Derived (calculated)
- Current assets (annual): USD 169.31MSEC XBRL filing
- Total assets (annual): USD 502.64MSEC XBRL filing
- Net income (annual): USD -177.97MSEC XBRL filing
- R&D expense (annual): USD 49.77MSEC XBRL filing
- Total operating expenses (annual): USD 312.53MSEC XBRL filing
- Shareholders' equity (annual): USD 245.78MSEC XBRL filing